What question did this study set out to answer?

To review the mechanisms, FDA-approved indications, landmark trial evidence, and NCCN guideline recommendations for immune checkpoint inhibitors in cancer therapy.

March 20, 2020SHILAP Revista de lepidopterologíaOpen Access

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

View Full Paper

Ask AI

Bookmark

Authors

RVRaju VaddepallyRegional Cancer Center PKPrakash KharelGeisinger Medical Center RPRamesh Kumar PandeyMinistry of Environment, Forests and Climate Change

Discussion

Member takes

Implication

Review details indications and evidence levels for immune checkpoint inhibitors in cancer patients, highlighting landmark trials guiding modern oncologic practice.

Key Points

To review the mechanisms, FDA-approved indications, landmark trial evidence, and NCCN guideline recommendations for immune checkpoint inhibitors in cancer therapy.
Analyzed clinical trial data and regulatory milestones for seven FDA-approved immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1.
Evaluated National Comprehensive Cancer Network (NCCN) evidence categories and clinical indications across solid and hematologic malignancies.
Blocking CTLA-4 or the PD-1/PD-L1 axis restores dysfunctional cytotoxic T-cell activity to promote anti-tumor immune responses.
Seven checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, and durvalumab) are approved across multiple cancer types with established NCCN evidence levels.

Cite This Study

Vaddepally et al. (2020) studied this question.

synapsesocial.com/papers/69d7d5dca2a48916bbbee093 https://doi.org/10.3390/cancers12030738

View Full Paper

Ask AI

Bookmark

Implication

Review details indications and evidence levels for immune checkpoint inhibitors in cancer patients, highlighting landmark trials guiding modern oncologic practice.

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Discussion

Member takes

Implication

Key Points

Cite This Study

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider